Additionally, a newly developed CXCR4 antagonist, PRX177561, has demonstrated a significant reduction in glioblastoma tumour growth and the potential to enhance the effects of anticancer chemotherapy and radiotherapy. The gene discussed is CXCR4; the disease is glioblastoma.